AI assistant
Arcus Biosciences, Inc. — Director's Dealing 2025
Sep 6, 2025
31966_dirs_2025-09-05_bf2a781d-220b-4ba1-b349-eedd17e1700b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2025-09-05
Reporting Person: Azoy Alexander (Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-05 | Common Stock | S | 1579 | $11.8797 | Disposed | 30194 | Direct |
Footnotes
F1: Consists of 1,579 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.55 to $12.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.